Connection

Payam Tabarsi to Middle Aged

Back to Details
This is a "connection" page, showing publications Payam Tabarsi has written about Middle Aged.
Payam Tabarsi
Connection Strength
0.157
Middle Aged
  1. Case Report: COVID-19-associated Rhinosinusitis Mucormycosis Caused by Rhizopus arrhizus: A Rare but Potentially Fatal Infection Occurring After Treatment with Corticosteroids. Am J Trop Med Hyg. 2021 Jul 08; 105(2):449-453.
    View in: PubMed
    Score: 0.015
  2. Combination therapy of IFNß1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients. Int Immunopharmacol. 2021 Mar; 92:107329.
    View in: PubMed
    Score: 0.015
  3. Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial. Int Immunopharmacol. 2021 Jan; 90:107205.
    View in: PubMed
    Score: 0.015
  4. Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial. Int Immunopharmacol. 2020 Dec; 89(Pt B):107102.
    View in: PubMed
    Score: 0.014
  5. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial. Int Immunopharmacol. 2020 Nov; 88:106869.
    View in: PubMed
    Score: 0.014
  6. Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial. Int Immunopharmacol. 2020 Aug; 85:106688.
    View in: PubMed
    Score: 0.014
  7. Diagnosis of COVID-19 by Serology in Admitted Patients with Negative RT-PCR Assay. Iran J Allergy Asthma Immunol. 2021 Aug 07; 20(4):394-401.
    View in: PubMed
    Score: 0.004
  8. Combined Therapy of Ciclosporin Plus Favipiravir in the Management of Patients with Severe COVID-19, not Responding to Dexamethasone: A non-Controlled Prospective Trial. Int Immunopharmacol. 2021 Oct; 99:108043.
    View in: PubMed
    Score: 0.004
  9. Increased Serum Levels of Soluble TNF-a Receptor Is Associated With ICU Mortality in COVID-19 Patients. Front Immunol. 2021; 12:592727.
    View in: PubMed
    Score: 0.004
  10. Prevalence of Anti-SARS-CoV-2 Specific Antibodies in Health-Care Workers Compared to General Population during an Early Phase of the Pandemic, Tehran-Iran. Iran J Immunol. 2021 03; 18(1):82-92.
    View in: PubMed
    Score: 0.004
  11. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial. Eur J Pharmacol. 2021 Apr 15; 897:173947.
    View in: PubMed
    Score: 0.004
  12. Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra. Int Immunopharmacol. 2021 Apr; 93:107407.
    View in: PubMed
    Score: 0.004
  13. Clinical and demographic characteristics of patients with COVID-19 infection: Statistics from a single hospital in Iran. Hum Antibodies. 2021; 29(1):49-54.
    View in: PubMed
    Score: 0.004
  14. Comparative evaluation of SARS-CoV-2 IgG assays against nucleocapsid and spike antigens. Hum Antibodies. 2021; 29(2):109-113.
    View in: PubMed
    Score: 0.004
  15. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. Lancet Infect Dis. 2021 04; 21(4):473-481.
    View in: PubMed
    Score: 0.004
  16. Silent hypoxia: higher NO in red blood cells of COVID-19 patients. BMC Pulm Med. 2020 Oct 16; 20(1):269.
    View in: PubMed
    Score: 0.004
  17. Prevalence and reversibility of smell dysfunction measured psychophysically in a cohort of COVID-19 patients. Int Forum Allergy Rhinol. 2020 10; 10(10):1127-1135.
    View in: PubMed
    Score: 0.004
  18. Extracorporeal membrane oxygenation and COVID-19: The causes of failure. J Card Surg. 2020 Oct; 35(10):2838-2843.
    View in: PubMed
    Score: 0.004
  19. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study. Transfus Apher Sci. 2020 Oct; 59(5):102875.
    View in: PubMed
    Score: 0.004
  20. Smell dysfunction: a biomarker for COVID-19. Int Forum Allergy Rhinol. 2020 08; 10(8):944-950.
    View in: PubMed
    Score: 0.004
  21. Blastocystis subtype 1 (allele 4); Predominant subtype among tuberculosis patients in Iran. Comp Immunol Microbiol Infect Dis. 2019 Aug; 65:201-206.
    View in: PubMed
    Score: 0.003
  22. Serum Exosomal miRNAs Are Associated with Active Pulmonary Tuberculosis. Dis Markers. 2019; 2019:1907426.
    View in: PubMed
    Score: 0.003
  23. Revision and Implementation of "Clinical Guideline for Tuberculosis and HIV in Prisons", Great Tehran Prison, Iran. Infect Disord Drug Targets. 2018; 18(1):72-80.
    View in: PubMed
    Score: 0.003
  24. Evidence for M2 macrophages in granulomas from pulmonary sarcoidosis: A new aspect of macrophage heterogeneity. Hum Immunol. 2018 Jan; 79(1):63-69.
    View in: PubMed
    Score: 0.003
  25. Distribution scheme of antituberculosis drug resistance among HIV patients in a referral centre over 10 years. J Glob Antimicrob Resist. 2017 12; 11:116-119.
    View in: PubMed
    Score: 0.003
  26. The effects of smoking on treatment outcome in patients newly diagnosed with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2017 03 01; 21(3):351-356.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.